Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model
Phase 1
Completed
- Conditions
- Norovirus Infection
- Interventions
- Biological: Norwalk GI.1 Virus
- Registration Number
- NCT03721549
- Lead Sponsor
- WCCT Global
- Brief Summary
There is a need for safe, highly infectious Norovirus inocula for use in Norovirus vaccine-challenge studies to assess the efficacy of Norovirus vaccines and examine the immune response among vaccinated and unvaccinated subjects. The purpose of this study is to generate the infection and illness rate and immune response data necessary for the conduct of future investigation of Norovirus vaccine studies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
- General good health, without significant medical illness, based on medical history, physical examination, vital signs, and clinical laboratories (CBC, chemistry, and urinalysis) as determined by the investigator in consultation with the research monitor and sponsor
- Available for all planned visits and to spend at least 5 days in confinement
- Confirmed blood type (A or O)
- Demonstrated to be H type-1 antigen secretor positive (by saliva test)
- Body mass index between 17 and 30 at screening
- Female subjects must have a negative pregnancy test and either use contraceptives or be sterile
- Available to return for follow-up visits following discharge from the inpatient unit and deliver stool specimens to the investigator promptly
Exclusion Criteria
- Presence of significant medical condition
- Donation or use of blood or blood products within 4 weeks prior to challenge
- Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make blood draws problematic
- Abnormal stool pattern
- Any gastroenteritis within the past 2 weeks
- Occupational hazards, including having daily contact with children under the age of 5, women known to be pregnant, employment in the food service industry, health care workers, etc.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Higher Dose Inoculum Norwalk GI.1 Virus Higher dose of Norwalk GI.1 Virus, 1x10\^6 genome copies Moderate Dose Inoculum Norwalk GI.1 Virus Moderate dose of Norwalk GI.1 Virus, 3.6x10\^5 genome copies
- Primary Outcome Measures
Name Time Method Frequency of Norovirus Gastroenteritis (NVG) 7 days post-challenge Occurrence of NVG within 7 days post-challenge
- Secondary Outcome Measures
Name Time Method Frequency of Serious Adverse Events (SAEs) 42 ± 3 days post-challenge Occurrence of SAEs
Trial Locations
- Locations (1)
WCCT Global
🇺🇸Costa Mesa, California, United States